LuPARP: This phase I trial is evaluating the combination of an oral therapy (olaparib) and a combination therapy (177Lu-PSMA) in patients with castration resistant prostate cancer that has spread to other parts of the body and progressed on other targeted treatments177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Summary

To be eligible for this trial, patients must have metastatic castration resistant prostate cancer (mCRPC) that has progressed with a novel AR targeted agent (abiraterone and/or enzalutamide and/or apalutamide) and has not previously been exposed to platinums, PARP inhibitors or 177Lu-PSMA. Patients can have had prior exposure to docetaxel in the chemotherapy naïve setting or castrate setting. Eligible patients will be enrolled in the trial in two stages: a dose escalation and expansion stage. Depending on the stage of enrolment, patients will receive either escalating or fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive up to 4 cycles of treatment.